- $7.69m
- $21.54m
- $8.51m
- 38
- 40
- 57
- 41
Annual cashflow statement for Evogene, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -26.2 | -30.4 | -29.8 | -26 | -18.1 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 5.35 | 1.86 | 4.37 | 1.41 | -1.69 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.39 | 1.64 | -0.689 | 0.265 | -2.46 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -19.5 | -24.7 | -23.7 | -21.6 | -19.7 |
| Capital Expenditures | -0.682 | -0.847 | -1.17 | -0.785 | -0.626 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 10.1 | -19.7 | 14.4 | -3.75 | 10.2 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 9.41 | -20.6 | 13.3 | -4.54 | 9.62 |
| Financing Cash Flow Items | 0.009 | 0 | 10 | — | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 20.4 | 30.3 | 9.34 | 18.2 | 4.66 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 11.5 | -13.9 | -3.35 | -8.21 | -5.47 |